Ginkgo Biloba: What the Evidence Actually Says

Ginkgo biloba extract has been used medicinally for thousands of years and remains one of the top-selling herbal supplements worldwide. In Europe, standardized ginkgo extract (EGb 761) is actually prescribed for cognitive symptoms. In the United States, it is sold as a supplement with claims about memory and cognitive support.

The problem is that ginkgo's reputation significantly outpaces its evidence base for its most popular use case: preventing cognitive decline and Alzheimer's disease. Understanding what the research actually shows — including a massive trial that failed to find what many hoped for — is essential before spending money on this supplement.

The mechanism: flavonoids and terpenoids

Ginkgo biloba leaf extract contains two primary classes of active compounds:

Flavonoids (flavone glycosides): Antioxidant compounds that appear to reduce oxidative stress, protect neurons from free radical damage, and have anti-inflammatory properties.

Terpenoids (ginkgolides and bilobalide): These compounds improve blood rheology (blood flow characteristics), inhibit platelet-activating factor (PAF), and may improve cerebral circulation.

The proposed mechanism linking ginkgo to cognitive benefits is primarily improved cerebral blood flow and antioxidant protection. Increased circulation to the brain could plausibly support cognitive function — particularly in aging brains where vascular contributions to cognitive impairment are significant.

The standardized extract EGb 761 (made by Dr. Willmar Schwabe GmbH) is the specific preparation used in most clinical research, standardized to 24% flavone glycosides and 6% terpene lactones. Importantly, not all ginkgo products on shelves match this standardization.

The GEM study: what the largest RCT found

In 2008, the Journal of the American Medical Association published the results of the Ginkgo Evaluation of Memory (GEM) study — the largest, most rigorous trial ever conducted on ginkgo biloba for Alzheimer's prevention. It enrolled 3,069 community-dwelling elderly adults (aged 75+), randomized them to 120 mg of EGb 761 twice daily (240 mg total) or placebo, and followed them for a median of 6.1 years.

The result was clear and disappointing for ginkgo proponents: ginkgo biloba did not reduce the rate of progression to Alzheimer's dementia or dementia from any cause compared to placebo. There was no difference in the rate of cognitive decline between the groups.

The GEM trial was large, long, well-funded, and used the same standardized extract that showed promising results in smaller earlier studies. Its null finding is highly credible and should be the anchor point for any discussion of ginkgo and Alzheimer's prevention.

Where ginkgo may still have a role

Despite the GEM trial's negative result for prevention, there is some evidence that ginkgo may help manage existing mild cognitive symptoms:

A 2016 meta-analysis in the Journal of Alzheimer's Disease (Tan et al.) reviewed 9 RCTs and found that EGb 761 at 240 mg/day was associated with statistically significant improvements on cognitive measures in people who already had dementia or mild cognitive impairment. These were treatment effects, not prevention effects.

Some research also supports ginkgo for vascular dementia specifically (where blood flow impairment is the primary driver), and for symptoms associated with normal aging like reduced processing speed and verbal recall — though effect sizes tend to be small.

Blood thinning risk: the safety issue that matters

Ginkgo significantly inhibits platelet aggregation through its PAF-inhibiting action. This creates real clinical risks:

Interaction with anticoagulants and antiplatelets: Ginkgo combined with warfarin, aspirin, clopidogrel, or similar drugs substantially increases bleeding risk. Case reports of spontaneous intracranial hemorrhage have been published.
Pre-surgical requirement: Most clinicians recommend stopping ginkgo at least 7-14 days before any surgery due to bleeding risk.
Drug interactions: Ginkgo also affects cytochrome P450 enzymes, which can alter the metabolism of many common medications.

Anyone on blood thinners, antiplatelet therapy, or preparing for surgery should not take ginkgo without explicit physician guidance.

Who ginkgo might help vs. who it will not

Potentially useful for:

Older adults with mild, existing cognitive symptoms (not for prevention)
People with vascular contributions to cognitive decline
Those seeking mild improvements in attention and processing speed (modest evidence)

Not supported by evidence for:

Preventing Alzheimer's disease in healthy older adults (GEM study)
Cognitive enhancement in young healthy adults
Replacing treatment for existing dementia

Product quality: EGb 761 matters

The standardized extract EGb 761 (24% flavone glycosides, 6% terpene lactones) is the form with clinical evidence. Generic ginkgo products may not meet this standardization, and some may contain ginkgolic acids — naturally occurring compounds that are allergenic and neurotoxic and should be minimized in quality products. Look for products that specify low ginkgolic acid content (under 5 ppm).

Typical research doses are 120-240 mg/day of EGb 761, split across two doses.

The bottom line

Ginkgo biloba does not prevent Alzheimer's disease — the GEM study settled that — but EGb 761 extract at 240 mg/day may modestly improve existing cognitive symptoms in older adults, provided users are aware of significant blood thinning risks and drug interactions.

Get an honest, evidence-based view of your supplement stack. Use Optimize free.

Supplements for Cognitive Decline Prevention: What the Evidence Shows